|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 45, 1640-1648, September 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

* HELIOS-Klinikum Berlin, Franz Volhard Clinic, Charité University Medicine in Berlin, and Max Delbrück Center for Molecular Medicine, Berlin, Germany
Department of Internal Medicine, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
Published, JLR Papers in Press, July 1, 2004. DOI 10.1194/jlr.M300322-JLR200
1 S. Engeli and J. Janke contributed equally to this work. ![]()
2 To whom correspondence should be addressed. e-mail: engeli{at}fvk.charite-buch.de
| ABSTRACT |
|---|
|
|
|---|
Increased eNOS and iNOS expression in adipocytes and local effects of insulin and Ang II may increase adipose tissue production of NO in obesity.
Supplementary key words adipocytes obesity hypertension insulin resistance adipogenesis
| INTRODUCTION |
|---|
|
|
|---|
1.5 nm and is thus ideally suited to act as a tissue hormone (1). Enzymes responsible for NO formation by rat and human adipose cells are the membrane-bound endothelial NO synthase (eNOS) and the cytoplasmically localized inducible NO synthase (iNOS) (26). In vitro, NO inhibits proliferation and stimulates the expression of two adipogenic marker genes, peroxisome proliferator-activated receptor
and uncoupling protein 1, in rat brown preadipocytes (7). Lipid accumulation and lipogenic enzymes are also induced by NO in rat white preadipocytes (8). Whereas increased NO formation may contribute to cold-associated vasodilation in brown adipose tissue in rats (2, 9), microdialysis measurements revealed that inhibition of NO synthesis does not influence adipose tissue blood flow in humans (4, 10, 11). Blocking NO synthesis abolished the cGMP-dependent suppressive effect of tumor necrosis factor-
on lipoprotein lipase activity in mouse brown adipocytes (12). In vivo, insulin-stimulated glucose uptake in rat white adipose tissue was dependent on intact NO synthesis (13). Basal as well as catecholamine-stimulated lipolysis were inhibited by NO in human and rat subcutaneous adipose tissue depots (4, 10, 11, 14, 15). Based on these findings, NO appears to be an important mediator of adipocyte physiology with lipogenic properties. Cytokine-dependent regulation of iNOS has already been described in fat cells (3, 5, 16), and we further characterized the influence of adipogenesis, obesity, and weight loss on genes belonging to the NO system in human adipose cells. Other obesity-associated hormones with known effects on adipocytes are insulin and angiotensin II (Ang II) (17, 18). Because both are known stimulators of eNOS activity in endothelial cells (19, 20), we also studied the influence of insulin and Ang II on eNOS activity in human adipose cells. | METHODS |
|---|
|
|
|---|
Stromavascular pellets from 25 g of adipose tissue were resuspended in 50 ml of red blood cell lysis buffer (0.154 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, and 10% fetal calf serum) and allowed to settle for 10 min at room temperature followed by a 10 min centrifugation at 380 g. The cell pellet was resuspended in serum-containing adipocyte medium, filtered through a 20 µm nylon mesh, and dispensed into 24 cm2 cell culture flasks. The cells were cultured to confluence until the next day. Adipogenesis in serum-free medium was induced over 1116 days by the continuous presence of 1 µM insulin, 1 nM triiodothyronine, and 100 nM hydrocortisone. Media were changed every 3 days. Conversion to the adipose phenotype, as monitored by staining intracellular lipids with Oil red O (21), was achieved in 6070% of the cells at day 11. For gene expression analysis, preadipocytes were trypsinized, washed once with phosphate-buffered saline, and pelleted (380 g, 10 min) at days 0, 2, 4, and 8. Primary cell cultures for these experiments were established from eight different subjects.
Gene expression analysis
All procedures (RNA isolation, cDNA synthesis, and TaqMan RT-PCR) were performed as described previously (22). In brief, total RNA was isolated by the Qiagen RNeasy mini kit (including the RNase-free DNase set) followed by the determination of quality and quantity with the Agilent 2100 bioanalyzer and the RNA 6000 Nano Chip. Two micrograms of total RNA was reverse transcribed in 20 µl final volume for 1 h at 37°C using 100 units of Superscript reverse transcriptase, 5.4 µg of random primer, 0.5 mM desoxyribonucleotide triphosphates (dNTPs), 10 mM DTT, and 1x RT buffer. Gene expression patterns of NO system genes were revealed by RT-PCR of RNA isolated from eight different paired samples of adipose tissue and adipocytes using the primer pairs, but not the probes, detailed in Table 1. RT-PCR conditions were the same as for the determination of quantitative gene expression with the complete TaqMan system (see below). PCR products were analyzed on DNA 500 Chips, and all PCR products were sequenced to verify specificity. Relative quantitation of gene expression was performed with the ABI 5700 sequence detection system for real-time PCR (TaqMan) using the standard curve method as described previously (22). Human GAPDH served as the endogenous control, as we previously demonstrated only small changes in GAPDH expression under the experimental conditions described in this paper (23). PCRs were performed with the TaqMan Universal Master Mix and the TaqMan assay reagent for GAPDH in a total volume of 25 µl. Sequences of primers and fluorescently labeled probes for NO system genes are given in Table 1. The two-step PCR conditions were 2 min at 50°C, 10 min at 95°C, and 45 cycles of 15 s at 95°C and 1 min at 62°C. Interassay coefficients of variation were 0.5% for eNOS and iNOS, 0.2% for guanylate cyclase ß-subunit (GUC Y1b3), 0.4% for cGMP-dependent protein kinase 1 (PRKG1), and 1.5% for GAPDH.
|
As eNOS activity is dependent on intracellular calcium availability, we tested the influence of Ang II on intracellular calcium concentrations in human preadipocytes. Human primary preadipocytes were cultured in a cover glass system in the medium mentioned above. Cells were loaded with 5 µM fura-2 acetoxymethyl ester (fura-2 AM) for 20 min at 37°C and then treated with 1 µM Ang II. Subsequently, preadipocytes were washed in PBS and postincubated in PBS for 10 min at 37°C to hydrolyze cytoplasmic fura-2 AM. Fluorescence imaging was performed with a fura-2 AM fluorescence imaging system (SPEX Fluorolog with attached Nikon Diaphot; excitation wavelengths, 340 and 380 nm; emission wavelength, 505 nm).
Clinical study protocols
The two study protocols were approved by the institutional ethics committee, and informed consent was obtained from all volunteers. In the first protocol, 30 postmenopausal women (defined as last bleeding more than 1 year ago) with no previous history of cardiovascular disorders (except hypertension) or obesity-associated metabolic disease (e.g., diabetes mellitus) were included. Before participating in the study, two of these women took vitamin D plus calcium for osteoporosis treatment, two took triiodothyronine because of increased thyroid volume with normal levels of the thyroid-stimulating hormone, and three were on nonsteroidal anti-inflammatory medication. All medication was stopped at least 7 days before the date of examination, and no woman was taking hormone replacement therapy. After an overnight fast, anthropometric measurements were performed at 8 AM followed by a 30 min bed rest, after which blood was drawn for hormonal and metabolic parameters. One to 4 g of subcutaneous abdominal adipose tissue was obtained from the periumbilical region by needle biopsy after intracutaneous local anesthesia with 1% lidocaine (without norepinephrine). Adipocytes were isolated from the biopsy material by collagenase digestion as described above and were snap frozen in liquid nitrogen for gene expression analysis immediately after the isolation process.
Insulin resistance was calculated using homeostasis model assessment (HOMA) based on fasting glucose (polarography; Beckman) and insulin (radioimmunoassay; DPC Biermann) levels in three blood samples drawn at 5 min intervals (25). Serum triglycerides and total cholesterol were determined by standard spectrophotometric procedures with kits from Roche Diagnostics (Mannheim, Germany). Blood pressure was determined by 24 h ambulatory blood pressure measurement (SPACELABS 90207; Spacelabs, Kaarst, Germany) starting 1 h after the biopsy. A cuff size of 14 cm was chosen for 2432 cm upper arm circumference, and 16 cm was chosen for >32 cm upper arm circumference. Subjects were divided into "lean" (BMI < 25 kg/m2) and "obese" (BMI > 30 kg/m2) groups.
In the second protocol, 10 postmenopausal women followed a weight reduction protocol including weekly counseling by a dietitian to reduce calorie intake by
600 kcal/day and underwater gymnastics once per week. All clinical measurements were identical to those in the first protocol, and adipose tissue samples were taken before the weight reduction protocol started and at the time when 5% weight loss had been reached, which was
13 weeks after the first biopsy. In this study, gene expression was determined in the adipose tissue samples and not in isolated adipocytes. All medication was stopped at least 7 days before the first biopsy, and hormone replacement therapy in this study was stopped 4 weeks before the first biopsy.
Materials
DMEM/Ham's F12, HBSS, HEPES, PBS, fetal calf serum, collagenase, L-glutamine, penicillin, streptomycin, cell culture flasks, and 24-well plates were obtained from Biochrom (Berlin, Germany). Insulin, hydrocortisone, triiodothyronine, panthotenate, biotin, glucose, EDTA, glutaraldehyde, Oil red O, Ang II, and isopropyl alcohol were purchased from Sigma-Aldrich Chemie and Sigma RBI (Taufkirchen, Germany). PCR primers, Superscript reverse transcriptase, 1x RT buffer, DTT, dNTPs, random primer, and kanamycin were from Life Technologies (Karlsruhe, Germany), and bovine serum albumin was from Biomol (Hamburg, Germany). The RNeasy Mini Kit and DNase Set were obtained from Qiagen (Hilden, Germany), and nylon filters were from neoLab (Heidelberg, Germany). Fluorescently labeled oligonucleotides were synthesized by BioTez (Berlin, Germany), and the Universal Master Mix and TaqMan assay reagent for GAPDH were from PE Biosystems (Weiterstadt, Germany). The RNA 6000 Nano Chips and the DNA 500 Chips were purchased from Agilent Technologies (Waldbronn, Germany). All reagents for NO measurements were obtained from Sigma RBI: Griess reagent (0.1% naphthylenediamine dihydrochloride, 1% sulfanilamide, and 2.5% H3PO4), sodium nitrate, and nitrate reductase. Fura-2 AM was purchased from Molecular Probes (Leiden, The Netherlands).
Statistics
Data are given as means ± SD or as median and range as appropriate and indicated in table and figure legends. Comparison between groups was by ANOVA and Bonferroni's multiple t-test as appropriate (NO production experiments), by Student's t-test for two independent groups (cross-sectional clinical study), by the nonparametric Wilcoxon's signed rank test for paired samples (weight loss study), and by the nonparametric Kruskal-Wallis test for multiple dependent groups (in vitro adipogenesis experiments). In the cross-sectional study, a multiple linear regression model was calculated for each gene that included age, BMI, the HOMA index of insulin resistance, and the systolic mean of ambulatory blood pressure as independent variables. Results were considered statistically significant at P < 0.05.
| RESULTS |
|---|
|
|
|---|
-subunits (GUCY1a2 and GUCY1a3) and one encoding a ß-subunit (GUCY1b3). The activation of the soluble guanylate cyclase by NO results in the formation of the second messenger cGMP, which activates the cGMP-dependent protein kinase, and both known human genes (PRKG1 and PRKG2) were expressed in mature human adipocytes. These RT-PCRs were not meant to measure quantitative differences in gene expression, but under identical PCR conditions the expression level of eNOS was obviously much higher than that of iNOS, both in adipose tissue and in isolated adipocytes. To clarify this finding, RT-PCR amplification plots for eNOS and iNOS were obtained in eight different samples of isolated human adipocytes by the fluorescence-based TaqMan method. The result for one sample is shown in Fig. 1. The difference of
3.5 PCR cycles corresponded to a 23.5 = 11.3-fold stronger expression level of eNOS compared with iNOS. Eight days of in vitro adipogenic differentiation increased the expression level of iNOS significantly, whereas eNOS expression levels were not influenced by this profound change in the cellular phenotype (Fig. 2)
.
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
-subunits (GUCY1a2 and GUCY1a3) and one encoding a ß-subunit (GUCY1b3). The activation of the soluble guanylate cyclase by NO results in the formation of the second messenger cGMP, which activates the cGMP-dependent protein kinase (28). Two isoforms encoded by two genes are known (PRKG1 and PRKG2), and both were expressed in mature human adipocytes. Based on our expression data, NO signaling molecules in human adipose cells appear largely similar to those in other tissues (1, 27, 28), thus explaining the biological effects of NO in human adipose tissue or isolated adipocytes (4, 11).
Earlier reports (6, 26) described
10-fold higher RNA and protein expression levels of eNOS compared with iNOS within identical human adipose tissue samples of men. We now confirmed this finding in isolated human adipocytes of postmenopausal women. Under basal physiological situations, eNOS appears to be the predominant NO synthase isoform in human adipose cells. Furthermore, eNOS expression did not increase during hormone-induced in vitro adipogenesis, suggesting that eNOS activity already contributes to preadipocyte biology. Rat preadipocytes and adipocytes have previously been shown to produce NO (8, 29). The fact that both insulin and Ang II stimulated NO production in human preadipocytes in our study further supports the presence of eNOS as an important NO synthase isoform in human adipose cells. Insulin and Ang II have been shown to induce eNOS gene expression in endothelial cells (19, 20); thus, a transcriptional mechanism may contribute to increased NO formation in our experiments. Insulin and Ang II, however, are also short-term activators of eNOS in endothelial cells, as Ang II increases intracellular calcium availability and insulin changes the phosphorylation status of eNOS through the activation of Akt and mitogen-activated protein kinases. In addition to the reported short-term effects of insulin in rat adipocytes on NO formation (29), we demonstrated here that Ang II in fact induces a substantial increase in intracellular calcium in human preadipocytes. Both short- and long-term actions of Ang II or insulin may act together to increase NO production.
Because NO has a role in the regulation of lipolysis, the influence of obesity and insulin resistance on the adipose NO system is clearly of interest. In 30 postmenopausal women, upregulation of eNOS and iNOS genes was observed in isolated abdominal subcutaneous adipocytes, accompanied by increased expression of the gene encoding cGMP-dependent protein kinase 1. These data confirm previous findings by Elizalde et al. (6) on eNOS expression in male adipose tissue. In contrast to their report, however, we also detected an increase in iNOS expression in obese subjects, which may be attributable to the fact that we studied isolated adipocytes, whereas their study explored adipose tissue. We cannot completely rule out the possibility that increased iNOS gene expression resulted from the process of isolating adipocytes, but it is unlikely that upregulation of iNOS expression would be more pronounced in the obese samples, leading to an artificial difference between groups. Furthermore, eNOS and iNOS gene expression were correlated to clinical variables. It is unlikely that artificially increased iNOS expression attributable to experimental procedures would yield data related to any phenotype. Thus it is reasonable to assume that the gene expression data of the clinical study reported herein reflect the in vivo situation. Furthermore, increased iNOS expression has recently been described in white adipose tissue of dietary as well as genetic animal models of obesity (30).
We found a clear increase in eNOS, iNOS, and PRKG1 gene expression in the obese group, but multiple linear regression revealed blood pressure as the statistically strongest variable to describe the increased expression of these three genes. The relationship between obesity and hypertension, however, is well known, and many confounding variables contribute to this relationship. Thus, in our opinion, the most justified notion would be that the clustering of higher body weight, some degree of hyperinsulinemia, and increased blood pressure leads to increased expression of these genes in obesity. In contrast, strong appraisal of one single variable, although statistically justified, may represent an overly simplistic view of the complex pathophysiology of obesity.
Several modulators of adipocyte gene expression may contribute to increased eNOS and iNOS expression: the influence of insulin and Ang II on eNOS expression in endothelial cells is well known (19, 20, 31). Thus, hyperinsulinemia (29) and increased local production of Ang II (32) in adipose tissue may increase eNOS gene expression in obese subjects. iNOS gene expression in adipocytes is increased by several cytokines, such as tumor necrosis factor-
and interferon-
(3, 5, 16), and increased tissue and plasma levels of several cytokines are part of the obesity syndrome (33, 34).
Our data and previously published data suggest increased NO formation in adipose tissue of obese individuals. What could be the possible role of increased adipose tissue NO production in the obesity syndrome? NO appears to enhance lipid storage by increasing insulin-stimulated glucose uptake and by decreasing basal and catecholamine-induced lipolysis (4, 10, 11, 1315). Thus, increased NO production in adipose tissue of obese individuals may contribute to decreased catecholamine-induced lipolytic rates, as typically described for subcutaneous adipose tissue depots of obese subjects (35).
The beneficial effects of NO formation on insulin-stimulated glucose uptake (13) are most likely explained by insulin-stimulated NO production in endothelial cells. NO may in turn facilitate glucose delivery into target organs (muscle and adipose tissue) by increasing tissue blood flow (16), and data from eNOS knockout mice point in the same direction, as these mice are prone to develop insulin resistance at the level of the liver and peripheral tissues (36). Further support for the role of normal NO levels in skeletal muscle and adipose tissue for the maintenance of normal glucose metabolism comes from studies on endothelial cell-specific insulin receptor knockout mice (31). These mice have impaired NO production by endothelial cells but normal glucose homeostasis under basal conditions. On a low-salt diet, however, a decrease in insulin sensitivity was observed that may be partly explained by changes in tissue blood flow under these conditions. In humans, however, no effects on adipose tissue blood flow have been seen by in vivo NO synthase inhibition (4, 10, 11).
In vitro data suggest that overproduction of NO by lipopolysaccharide-induced iNOS stimulation inhibited insulin-stimulated glucose uptake in muscle cells but not in mouse clonal preadipocyte cell lines (16). Thus, cell type-specific effects of NO on glucose uptake have to be considered, as well as the fact that NO may act directly (as seen in vitro) or indirectly by influencing blood flow in vivo. A specific role for iNOS has been suggested in animal studies: targeted disruption of the iNOS gene in mice led to a phenotype with increased insulin sensitivity and resistance to the development of high-fat diet-induced insulin resistance in skeletal muscle (30). Furthermore, AMP-activated kinase-mediated posttranslational phosphorylation inhibited iNOS activity and enhanced insulin sensitivity in muscle and adipose tissue (37).
Taken together, the following scenario might describe the role of NO for metabolic regulation in lean animals: constitutive formation of NO by eNOS is important for normal levels of insulin sensitivity, whereas the contribution of iNOS under situations of iNOS activation may be linked to a deterioration of insulin sensitivity. In humans, however, the balance of iNOS and eNOS is not as clear as in rodents, at least not in adipose tissue. Because of the lack of data, one can only speculate that increased NO production in obese individuals may impair insulin-stimulated glucose uptake or contribute at least to decreased lipolytic rates in subcutaneous adipose tissue, which may contribute to increased lipid storage. This hypothesis, however, needs further testing.
| ACKNOWLEDGMENTS |
|---|
Manuscript received July 22, 2003 and in revised form January 28, 2004. and in re-revised form June 11, 2004.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. R. Kaun, M. Chakaborty-Chatterjee, and M. B. Sokolowski Natural variation in plasticity of glucose homeostasis and food intake J. Exp. Biol., October 1, 2008; 211(19): 3160 - 3166. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dallaire, K. Bellmann, M. Laplante, S. Gelinas, C. Centeno-Baez, P. Penfornis, M.-L. Peyot, M. G. Latour, J. Lamontagne, M. E. Trujillo, et al. Obese Mice Lacking Inducible Nitric Oxide Synthase Are Sensitized to the Metabolic Actions of Peroxisome Proliferator-Activated Receptor-{gamma} Agonism Diabetes, August 1, 2008; 57(8): 1999 - 2011. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Kaun, C. A. L. Riedl, M. Chakaborty-Chatterjee, A. T. Belay, S. J. Douglas, A. G. Gibbs, and M. B. Sokolowski Natural variation in food acquisition mediated via a Drosophila cGMP-dependent protein kinase J. Exp. Biol., October 15, 2007; 210(20): 3547 - 3558. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Ahmed, N. D.L. Fisher, and N. K. Hollenberg Gender and the Renal Nitric Oxide Synthase System in Healthy Humans Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 926 - 931. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Sautin, T. Nakagawa, S. Zharikov, and R. J. Johnson Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress Am J Physiol Cell Physiol, August 1, 2007; 293(2): C584 - C596. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Engeli, M. Boschmann, F. Adams, G. Franke, K. Gorzelniak, J. Janke, F. C. Luft, and J. Jordan Dissociation between Adipose Nitric Oxide Synthase Expression and Tissue Metabolism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2706 - 2711. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Linscheid, D. Seboek, H. Zulewski, A. Scherberich, N. Blau, U. Keller, and B. Muller Cytokine-induced metabolic effects in human adipocytes are independent of endogenous nitric oxide Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1068 - E1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Celis, J. M. A. Moreira, T. Cabezon, P. Gromov, E. Friis, F. Rank, and I. Gromova Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients: Toward Dissecting The Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions Mol. Cell. Proteomics, April 1, 2005; 4(4): 492 - 522. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |